Oral sessions summaries
Tofacitinib for the treatment of adult patients with ankylosing spondylitis: primary analysis of a phase 3, randomized, double-blind, placebo-controlled study
ACR Convergence 2020 - Oral session summaries - Abs #L11
Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis: 1-year results from a randomized, double-blind, placebo-controlled study with open-label extension
ACR Convergence 2020 - Oral session summaries - Abs #2023
Secukinumab provides sustained improvements in clinical and imaging outcomes in patients with psoriatic arthritis and axial manifestations: results from the MAXIMISE trial
ACR Convergence 2020 - Oral session summaries - Abs #0505
Disease-related factors associated to atherosclerotic disease in axial spondyloarthritis. A multicenter study with 806 patients
ACR Convergence 2020 - Oral session summaries - Abs #0448
Predictors of maintaining inactive disease after etanercept withdrawal, and regaining inactive disease status after flare and retreatment, in adults with non-radiographic axial spondyloarthritis: results from RE-EMBARK
ACR Convergence 2020 - Oral session summaries - Abs #2028
Efficacy of apremilast for the treatment of manifestations of Behçet’s syndrome other than oral ulcers, including skin lesions and arthritis
ACR Convergence 2020 - Oral session summaries - Abs #0512
Characteristics of giant cell arteritis flares after successful treatment with tocilizumab: results from the long-term extension of a randomized controlled phase 3 trial
ACR Convergence 2020 - Oral session summaries - Abs #0516
Two-year results from a randomized, controlled study of obinutuzumab for proliferative lupus nephritis
ACR Convergence 2020 - Oral session summaries - Abs #0988
Efficacy and safety of guselkumab, a monoclonal antibody specific to the p19-subunit of interleukin-23, through week 52 of a phase 3, randomized, double-blind, placebo-controlled study conducted in biologic-naïve patients with active psoriatic arthritis
ACR Convergence 2020 - Oral session summaries - Abs #0506
Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and inadequate response to biologic disease-modifying anti-rheumatic drugs: a double-blind, randomized controlled phase 3 trial
ACR Convergence 2020 - Oral session summaries - Abs #0504
Efficacy and safety of tildrakizumab, a high-affinity anti–interleukin-23p19 monoclonal antibody, in patients with active psoriatic arthritis in a randomized, double-blind, placebo-controlled, multiple-dose, phase 2b study
ACR Convergence 2020 - Oral session summaries - Abs #2027
Integration of clinical and protein markers through machine learning to distinguish patients with psoriasis arthritis from those with psoriasis without psoriatic arthritis
ACR Convergence 2020 - Oral session summaries - Abs #0502
Multimorbidity in rheumatoid arthritis, psoriatic arthritis, gout, and osteoarthritis within the Rheumatology Informatics System for Effectiveness (RISE) registry
ACR Convergence 2020 - Oral session summaries - Abs #2021
The reliability of scoring sonographic entheseal abnormalities – the Diagnostic Ultrasound Enthesitis Tool (DUET) study
ACR Convergence 2020 - Oral session summaries - Abs #2021
Prevalence, incidence, and cause-specific mortality of rheumatoid arthritis-associated interstitial lung disease among older patients with rheumatoid arthritis: a nationwide cohort study
ACR Convergence 2020 - Oral session summaries - Abs #0489
A phase 2b, randomized, double-blind study in patients with rheumatoid arthritis evaluating the safety and efficacy of evobrutinib compared with placebo in patients with an inadequate response to methotrexate
ACR Convergence 2020 - Oral session summaries - Abs #2012
Non-obese rheumatoid arthritis patients with low low-density lipoprotein have higher coronary atherosclerosis burden, greater plaque progression and cardiovascular event risk
ACR Convergence 2020 - Oral session summaries - Abs #0485
Stable versus tapered and withdrawn treatment with tumor necrosis factor inhibitor in rheumatoid arthritis remission: a randomized, open-label, phase 4, non-inferiority trial
ACR Convergence 2020 - Oral session summaries - Abs #2010
Incidence and risk factors for herpes zoster in rheumatoid arthritis patients receiving upadacitinib
ACR Convergence 2020 - Oral session summaries - Abs #1002
Can a Clinical Disease Activity Index based on patient-reported joint counts (PT-CDAI) be used to inform target-based care in telemedicine? An analysis of 2 early RA cohort studies
ACR Convergence 2020 - Oral session summaries - Abs #0483
